Postmenopausal endometrial hyperplasia: role of danazol therapy

L. Mariani, A. Sedati, R. Giovinazzi, R. Sindico, G. Atlante

Research output: Contribution to journalArticlepeer-review


OBJECTIVES: To confirm the effectiveness of danazol in the management of simple or complex endometrial hyperplasia without atypical features, as has been demonstrated previously. METHODS: Seventy-six patients affected by postmenopausal histologically-confirmed endometrial hyperplasia with uterine bleeding were submitted to danazol therapy at a dose of 400 mg/day for 3 consecutive months. RESULTS: After cessation of treatment, 82.8% of the patients (63/76 enrolled) showed a conversion of the hyperplasia into atrophic (65.8%), secretory (11.9%) or proliferative (4.2%) endometrium at the histological examination. Uterine bleeding disappeared, during the therapy, in 90% of the responders (59/63). CONCLUSIONS: Although 17.1% of the women had a persistence of the hyperplasia and 8.4% of the symptom-free women relapsed after 4 months of follow-up, this experience confirms the effectiveness of danazol therapy in hyperplastic endometrial lesions. Nevertheless, a study comparing danazol and progestin therapy is required.

Original languageEnglish
Pages (from-to)155-159
Number of pages5
JournalInternational Journal of Gynecology and Obstetrics
Issue number2
Publication statusPublished - 1994


  • Danazol
  • Endometrial hyperplasia

ASJC Scopus subject areas

  • Obstetrics and Gynaecology


Dive into the research topics of 'Postmenopausal endometrial hyperplasia: role of danazol therapy'. Together they form a unique fingerprint.

Cite this